Germany In Vitro Fertilization (IVF) Market Expected to Reach $541 Million, by 2026

 

According to a new report published by Allied Market Research, titled, "Germany In Vitro Fertilization (IVF) Market by Cycle Type and End User: Opportunity Analysis and Industry Forecast, 2019-2026", The Germany IVF market was valued at $398 million in 2018 and is estimated to reach $541 million by 2026, registering a CAGR of 3.9% during the analysis period.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/5483

 

Absence of ability or diminished ability to conceive and bear an offspring is termed as infertility. In vitro fertilization (IVF) is a process that is employed to conceive artificially. The process includes five basic steps such as stimulation, egg retrieval, insemination and fertilization, embryo culture, and embryo transfer. The entire process is performed outside the body and once the embryo is ready, it is implanted in the uterus. In the process fertilization occurs outside the body in a laboratory medium. In vitro fertilization is most often tried when other, less expensive, or invasive fertility techniques have failed. 

The major factors that boost the growth of the Germany in vitro fertilization market are subsidizing IVF treatments, delayed marriages & parenting decisions, and rise in number of infertility cases. Furthermore, as per National Health Plan (NHP), about 50% of the treatment cost by IVF paid for three cycles is anticipated to drive the growth of the IVF market in Germany. However, stringent government regulations and lack of availability in treatment cycles for IVF are the major restraints that hinder the growth of the market in Germany. Moreover, surge in adoption of IVF technique in the country is expected to provide remunerative opportunities during the forecast period.

According to cycle type, the fresh IVF cycles acquired the largest Germany in vitro fertilization market share in 2018 owing to increased stability offered by the technique. Moreover, the technique has better outcomes when compared to other techniques which boots the growth of this market. Furthermore, thawed IVF cycles is expected to grow with fastest rate during the forecast period owing to the surge in infertility in the region coupled with the increase in number of IVF clinics.

Based on end user, the fertility clinics in the end user segment generated the highest revenue in 2018. The fertility clinics segment is the largest and the fastest growing segment during the forecast period owing to the presence of large number of fertility clinics.

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/5483

 

Key Findings of the Germany In Vitro Fertilization (IVF) Market :

• By cycle type, fresh IVF cycles in Germany IVF market accounted for largest share in 2018.
• By end user, the fertility clinics segment accounted for three-fourths of the market share in 2018.
• By end user, the clinical research institutes segment is anticipated to account for one-sixth share of the market in 2018.

 

India In Vitro Fertilization (IVF) Services Market Expected to Reach $1,453.0 Million, by 2026

 

According to a new report published by Allied Market Research, titled, " India In Vitro Fertilization (IVF) Services Market by Gender, Procedure, Cycle Type, End User and Offerings: Opportunity Analysis and Industry Forecast, 2019-2026 ", The India IVF services market Size was valued at $478.2 million in 2018 and is estimated to reach $1,453.0 million by 2026, registering a CAGR of 14.7% during the analysis period.

In vitro fertilization (IVF) is the fertilization process of a woman's egg and a man's sperm, in this process mature eggs are collected (retrieved) from ovaries and fertilized by sperm in a laboratory. Then the fertilized egg is transferred to a uterus. This treatment is for women with the infertility or genetic problems. This technique is used to help a woman become pregnant. Fertilization process means the sperm has attached to and go in the egg. In vitro fertilization (IVF) is a form of an assisted reproductive technology (ART). 

 

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/2172

 

 The major factor that boost the growth of the India in vitro fertilization services market are such as increase in the infertility rates caused due to surge in stress levels, surge in incidence of fertility-related diseases and changes in lifestyle. Further, emerging trend of delayed pregnancies among women, and increase in occurrences of gamete donations boosts the market. However, low awareness toward this technique in the society are certain factors which hinders the growth of the India IVF services market. Moreover, rise in the prevalence due to increase in risk factors, such as obesity, stress, polycystic ovarian syndrome (PCOS), sexually transmitted infections, endometrial tuberculosis, and other medical conditions, is expected to offer lucrative opportunities for market growth during the forecast period.

The India IVF services market is segmented based on gender, procedure, cycle type, offering and end user. Based on gender, it is divided into female infertility, male infertility, and both (combined) infertility. Based on procedure, it is classified into intracytoplasmic sperm injection (ICSI-IVF), non-ICSI-IVF, and intrauterine insemination (IUI). Based on cycle type, the market is categorized into fresh cycle (non-donor), thawed cycle (non-donor), and donor egg IVF cycle. Based on offering segment is divided into IVF drugs, IVF media and reagents and IVF and IUI services. Based on end user, it is segmented into fertility clinics, hospitals, surgical centers, and clinical research institutes.

Based on end user, the fertility clinics in the end user segment generated the highest revenue in 2018. The fertility clinics segment is the largest and the fastest segment during the forecast period owing to presence of large number of fertility clinics and availability and accessibility of different services related to IVF such as infertility treatment, IVF programs, egg donation, sperm donation, intracytoplasmic sperm injection (ICSI), intra-cytoplasmic morphologically selected sperm injection (IMSI), and others. Further, fertility clinics are expected to grow with fastest rate during the forecast period. 

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2172

 

Key Findings of the India IVF Services Market :

• By gender, female fertility in India in vitro fertilization services market accounted for largest share in 2018.
• By procedures, ICSI IVF in India IVF services market accounted for largest share in 2018.
• By cycle type, fresh IVF cycles in India in vitro fertilization services market accounted for largest share in 2018.
• By end user, fertility clinics segment in India IVF services market accounted for largest market share in 2018.
• By offering, IVF and IUI Services in India in vitro fertilization services market accounted for largest market share in 2018.

 

3D Printed Drugs Market Expected to Reach $522 Million by 2030

 According to a new report published by Allied Market Research, titled, 3D Printed Drugs Market by Forecast Scenario Analysis: Global Opportunity Analysis and Industry Forecast, 2017-2030, Spritam is the only 3D printed drug available in the market since 2016 to treat epilepsy. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. U.S. market holds the highest market share in 2020.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4508

 

3D printed drugs are medications created by 3D printing technology that are used to treat patients suffering from dysphagia. 3D printed drugs have porous structures that can disintegrate rapidly inside the mouth itself. Aprecia Pharmaceuticals Companys SPRITAM levetiracetam is the first 3D printed drug, which has been approved by the U.S. Food and Drug Administration (FDA) in August 2015.

Constant technological developments in 3D printing technique, rise in incidence of epilepsy cases, and increase in awareness about the 3D printing technology in the developing countries drive the growth of the market. However, lack of government regulations related to these drugs and adverse effects of 3D printed drugs are expected to limit the market growth.

The global 3D printed drugs market is analyzed based on forecast scenario such as low growth scenario, moderate growth scenario, and rapid growth scenario.

According to low growth scenario, the U.S. is anticipated to account for the highest market share in 2020, and rest of North America market is expected to grow at the highest rate, registering the CAGR of 5.1% by 2030.

Europe is estimated to account for four-sevenths share in 2020, and is expected to dominate the market throughout the forecast period, due to presence of well-established healthcare systems and increase in prevalence of dysphagia. In addition, increase in adoption of 3D printed drugs is anticipated to provide new growth opportunities for the key players in the European market. However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to increase in healthcare expenditure, rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4508

Key Findings of 3D Printed Drugs Market:

• In North America, the U.S. is anticipated to dominate the market in 2020, whereas rest of North America is projected to grow at the highest CAGR during the forecast period.
• Germany was the major shareholder in the European 3D printed drugs market in 2016.
• Asia-Pacific is expected to register the highest growth rate in future.
• Australia is expected to grow at the highest CAGR in the Asia-Pacific 3D printed drugs market.

The key players profiled in this report include Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, 3D Printer Drug Machine, and FabRx Ltd.

The organizations engaged in the research of 3D printed drugs included in this report are UCL School of Pharmacy, University of Glasgow, University College London, The University of Nottingham, and National University of Singapore.

Automatic Pill Dispenser Machine Market Expected to Reach $3,023 million by 2023

 

According to a new report published by Allied Market Research, titled, Automatic Pill Dispenser Machine Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2017-2023, the global automatic pill dispenser machine market was valued at $1,755 million in 2016, and is projected to reach $3,023 million by 2023, growing at a CAGR of 8% from 2017 to 2023. The centralized automated dispensing systems segment held more than four-fifths share of the total market in 2016.

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4329

 

 Automatic pill dispenser machines are designed to dispense different pills independently according to the user-defined dose and time specifications. The automatic pill dispenser machine support to dispense correct medication and dose, for the patients with complex medication regime and with memory loss disorders.

Based on the type, the centralized automated dispensing systems segment held the highest market share in 2016, owing to various benefits of the machines such as point-of-care availability, their capability to control storage & distribution, and maintain record of medicines.

Based on application, the hospital pharmacy segment contributed the highest market share in 2016, owing to the increase in need of fast and accurate dispensing of medicines in the hospitals and pharmacy.

North America accounted for more than half of the share in 2016, and is expected to dominate the market throughout the forecast period and is attributed to rise in expenditure to upgrade healthcare systems and growth in demand for technologically advanced devices for rapid & accurate distribution of medicines. In addition, lucrative growth opportunities in the economic emerging countries is anticipated to provide new growth opportunities for the key players in the market. However, Asia-Pacific is estimated to register the highest growth rate during the forecast period, owing to rise in government healthcare expenditure and growth in demand for healthcare devices from large pool of patient population, and improvement in healthcare infrastructure.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4329

 Key Findings of the Automatic Pill Dispenser Machine Market:

• By type, the centralized automated dispensing system segment dominated the market in 2016, and is projected to grow at the highest CAGR.
• By application, the hospital pharmacy segment accounted for the highest share in 2016.
• The U.S. was the major shareholder in the North America cardiac surgical devices market in 2016.
• Asia-Pacific is expected to show the highest growth rate during the analysis period.
• China is expected to grow at the highest CAGR in the Asia-Pacific market.

Major companies operating in this market adopt product launch as their key development strategy. Companies profiled in this market include, Baxter International Inc., Becton, Dickinson and Company, Cerner Corporation, Capsa Healthcare, McKesson Corporation, Omnicell Inc., ScriptPro LLC, Swisslog Holdings AG, Talyst, Inc., and Yuyama Co., Ltd.

Other prominent players in the value chain include Illinois Tool Works, Pearson Medical Technologies, Accu-Chart Plus Healthcare System, Allscripts Healthcare Solutions, Inc., Meditech, Constellation Software Inc., and Optum Inc.

In Vitro Diagnostics (IVD) Market Expected to Reach $91 Billion by 2027

 

According to a new report published by Allied Market Research, titled, "In Vitro Diagnostics Market by Product & Service, Technique, Application, and End User:  Opportunity Analysis and Industry Forecast, 2020–2026," the global in vitro diagnostics market size was valued at $67 billion in 2019, and is expected to reach $91 billion by 2027, registering a CAGR of 4.8% from 2020 to 2027. 

 

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/336

 

In vitro diagnostics is defined as medical devices which are used by laboratories to perform diagnostic tests inside a laboratory. These tests are performed on samples collected from a patient’s body such as blood, urine, and tissues. Furthermore, medical devices used to perform in vitro diagnosis also require the use of various technologies to conduct the tests. For instance, blood collected from a patient is analyzed for hepatitis infection by using enzyme linked immunosorbent assay technique to analyze the blood. Furthermore, the testing procedure also requires use of various reagents and the use of software for smooth operations. In addition, in vitro diagnostics are used for detection of various medical conditions such as infectious diseases, diabetes, oncology/cancer, cardiology diseases, autoimmune diseases, nephrology, and HIV/AIDS. Moreover, these tests are performed in various medical facilities such as hospitals, standalone laboratories, and academic & medical schools.

 

Factors such as rise in awareness about healthcare, surge in incidences of chronic and infectious disease, and cost-effective diagnostic solutions are boost the growth of the in vitro diagnostics market. Similarly, rise in use of automated instruments and point-of-care diagnostic solutions, surge in government expenditure on healthcare globally, and accurate and faster test results supplement the in vitro diagnostics market growth. However, stringent regulations & policies and unclear reimbursement rules hamper the market growth. Moreover, high growth rate exhibited by developing economies are expected to present lucrative opportunities for key players in the in vitro diagnostics market during the forecast period. 

 

The report segments the market across into product & service, technique, application, end user, and region. On the basis of product & service, the market is segmented into reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into types such as enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELSIA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others.

 

The clinical chemistry segment is also further divided basic metabolic panel, liver panel, lipid profile, thyroid function panel, electrolyte panel, specialty chemicals, and others.

On the basis of product & service, the reagents segment acquired the major share of in vitro diagnostics market. The growth of this segment is attributed to the fact that reagents are a vital part of every in-vitro diagnostic test. Hence, the factors aforementioned contribute to the growth of this segment. In addition, the instruments segment is expected to grow at the fastest CAGR during the forecast period, owing to rise in focus of key players toward launching of new instruments. 

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/336

 

North America is expected to be the leading regional market for IVD during the forecast period, owing to its well-penetrated healthcare system and higher healthcare awareness among patients, including Obama’s Affordable Care Act (ACA) act, change in technology, and rebounding American Economy. Furthermore, other factors such as easy availability of devices, rise in the awareness related to use of these products and presence of large number of geriatric populations suffering from various chronic diseases also contribute to the growth of the market. Moreover, presence of large number of key players in North America is another major factor that drives the growth of the market. In addition, Asia- Pacific is expected to register fastest growth rate during the forecast period, owing to surge in healthcare expenditure and rise in prevalence of diabetes in the region. Other factors such as huge patient base of other chronic diseases that require IVD testing also boost the growth of market in Asia-Pacific.

 

Key Findings Of The Study 

·         The reagents segment accounted for more than half of the share of the global in vitro diagnostics market in 2019.

·         The instruments segment is expected to grow at the highest CAGR from 2020 to 2027.

·         The infectious diseases segment accounted for around one-thirds share of the global in vitro diagnostics market in 2019.

·         Europe accounted for around one-fifth share of the global market in 2019.

·         Asia-Pacific is expected to provide lucrative growth opportunities from 2019 to 2027.